NHS patients with advanced anal cancer are set to benefit from a landmark new treatment that can extend survival by almost a year, in what cancer experts have described as one of the most significant advances for the disease in decades.
The NHS has begun rolling out retifanlimab, a pioneering immunotherapy that helps the body's immune system identify and attack cancer cells. The treatment will be available to around 250 eligible patients each year whose anal cancer has spread or returned locally and can no longer be removed through surgery.
The decision follows the results of a major clinical trial, which demonstrated that patients receiving retifanlimab alongside chemotherapy lived an average of 32.8 months, compared with 22.2 months for those treated with chemotherapy alone. Some patients also experienced significantly longer-lasting responses to treatment.
The treatment has been approved for use across the UK following a recommendation from the National Institute for Health and Care Excellence (NICE) and has been made available to NHS patients within days, thanks to collaboration between healthcare organisations and the NHS's accelerated access programmes.
Funding for the treatment comes through NHS England's Cancer Drugs Fund, which is designed to give eligible patients faster access to innovative medicines while supporting rapid adoption across the health service.
Around 1,600 people are diagnosed with anal cancer each year in the UK, with incidence rates increasing significantly over recent decades. While early-stage anal cancer can often be treated successfully, options for patients with advanced disease have historically been limited.
Retifanlimab represents the first immunotherapy specifically approved for advanced anal cancer, providing a new treatment pathway for a patient group that has seen relatively few therapeutic breakthroughs.
Professor Peter Johnson, National Clinical Director for Cancer at NHS England, said:
“Access to this life-extending drug is one of the most significant steps in decades for people living with advanced anal cancer – and this treatment can give them precious extra time with their family and loved ones.
“For a type of cancer which has become more common, and where very few new treatments have been invented, this represents major progress, and NHS fast-tracking access to the drug means eligible patients can start benefiting from it straight away.”
Manufactured by Incyte Biosciences, retifanlimab is administered through an intravenous drip every four weeks for up to one year. Patients will initially receive the immunotherapy alongside standard chemotherapy treatment.
The rapid approval and rollout highlight the growing role of immunotherapy within cancer care, with NHS leaders increasingly looking to innovative treatments that can improve survival rates and quality of life for patients with hard-to-treat cancers.
For oncology teams and NHS trusts, the introduction of retifanlimab marks a significant development in the treatment landscape, offering fresh hope to patients facing advanced anal cancer and reinforcing the NHS's commitment to accelerating access to cutting-edge therapies.
Image credit: iStock
